EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas

Vebjørn Kvikstad, Melinda Lillesand iD, Einar Gudlaugsson, Ok Målfrid Mangrud, Emma Rewcastle, Ivar Skaland, Jan P A Baak, Emiel A M Janssen

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0297141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Vebjørn Kvikstad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stavanger University Hospital, Stavanger, Norway. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stavanger University Hospital, Folke Hermansen Foundation and Western Norway Regional Health Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-muscle invasive papillary urothelial carcinoma is a prevalent disease with a high recurrence tendency. Good prognostic and reproducible biomarkers for tumor recurrence and disease progression are lacking. Currently, WHO grade and tumor stage are essential in risk stratification and treatment decision-making. Here we present the prognostic value of proliferation markers (Ki67, mitotic activity index (MAI) and PPH3) together with p53, CD25 and CK20 immunohistochemistry (IHC). In this population-based retrospective study, 349 primary non-muscle invasive bladder cancers (NMIBC) were available. MAI and PPH3 were calculated manually according to highly standardized previously described methods, Ki-67 by the semi-automated QPRODIT quantification system, p53 and CD25 by the fully automated digital image analysis program Visipharm ® and CK20 with the help of the semi-quantitative immunoreactive score (IRS). Survival analyses with log rank test, as well as univariate and multivariate Cox regression analyses were performed for all investigated variables. Age and multifocality were the only significant variables for tumor recurrence. All investigated variables, except gender, were significantly associated with stage progression. In multivariate analysis, MAI was the only prognostic variable for stage progression (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in SituHumansTumor Suppressor Protein p53ImmunohistochemistryNeoplasm Recurrence, LocalRetrospective StudiesBiomarkers, TumorKi-67 AntigenPrognosisCell Proliferation

Substanzen

Tumor Suppressor Protein p53Biomarkers, TumorKi-67 Antigen

Autor:innen und Institutionen

  • Department of Pathology, Stavanger University Hospital, Stavanger, Norway.
  • Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway.
  • Cancer Registry of Norway, Oslo, Norway.
  • Dr. Med. Jan Baak AS, Tananger, Norway.

ORCID-Profile: Melinda Lillesand

Förderung

  • Stavanger University Hospital, Folke Hermansen Foundation and Western Norway Regional Health Authority

Zitieren

APA

Kvikstad, V., Lillesand, M., Gudlaugsson, E., Mangrud, O. M., Rewcastle, E., Skaland, I., Baak, J. P. A., & Janssen, E. A. M. (2024). Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas. PLOS ONE. https://doi.org/10.1371/journal.pone.0297141

Vancouver

Kvikstad V, Lillesand M, Gudlaugsson E, Mangrud OM, Rewcastle E, Skaland I, et al. Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas. PLOS ONE. 2024. doi:10.1371/journal.pone.0297141

BibTeX
@article{Kvikstad2024,
  author = {Kvikstad, Vebjørn and Lillesand, Melinda and Gudlaugsson, Einar and Mangrud, Ok Målfrid and Rewcastle, Emma and Skaland, Ivar and Baak, Jan P A and Janssen, Emiel A M},
  title = {Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0297141}
}
Kostenlos starten →